Source: European Medicines Agency (EMA)
Area: News
The European Medicines Agency (EMA) has announced that it has been formally notified by Lux Biosciences GmbH of its decision to withdraw its application for a centralised marketing authorisation for t…
Author: NeLM - Ophthalmology
MeReC Rapid Review: Most people with acute infective conjunctivitis don’t need antibiotics
Source: NPC
Area: News
The National Prescribing Centre has published a MeReC Rapid Review discussing the results of a meta-analysis that found a small overall significant benefit of topical antibiotics in acute infective conjunctivitis; however no sig…
EU marketing authorisation application for voclosporin (Luveniq®) withdrawn
Source: European Medicines Agency
Area: News
The European Medicines Agency (EMA) has announced the withdrawal of the application for a centralised marketing authorisation for voclosporin (Luveniq®), which was intended to be used for the treatment of…
Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review
Source: Patient Preference and Adherence
Area: Evidence > Medicines Management > References
Purpose: This study summarises findings from objective assessments of compliance (or adherence) and persistence with ocular hypotensive agents in patients with…
Antioxidants and zinc for age-related macular degeneration
Source: North West Medicines Information Centre
Area: Evidence > Medicines Q & A
Age-related macular degeneration (AMD) is a leading cause of visual loss in the Western world; older age, genetic markers and cigarette smoking are risk factors. …
Scottish Medicines Consortium does not recommend bromfenac (Yellox) eye drops due to non submission
Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
In the absence of a submission from the holder of the marketing authorisation, the Scottish Medicines Consortium (SMC) does not recommend bromfenac (Yellox ®) eye drop…
MSD update on shortage of preservative-free ophthalmic products
Source: Personal communication
Area: News
MSD UK is currently experiencing a shortage in the supply of Trusopt preservative free eye drops, Timoptol (timolol maleate) preservative-free ophthalmic solution 0.25% and Timoptol preservative-free ophthalmi…
Study investigates associations between aspirin use and AMD
Source: Ophthalmology
Area: News
Results from an analysis of the European Eye Study (EES), published early online in the journal Ophthalmology, suggest that there may be an association with use of daily aspirin and age-related macular degeneration (AM…
Expert attacks decision in US to stop use of bevacizumab for eye condition
Source: British Medical Journal (BMJ)
Area: News
A leading specialist has criticised the US Department of Veterans Affairs’ decision to stop using bevacizumab (Avastin®) for wet age related macular degeneration (AMD), due to a possible increased risk…
NHS Choices ‘Behind the Headlines’ assessment of press reports that a stem cell trial for an eye condition is to go ahead
Source: NHS Choices
Area: News
The ‘Behind the Headlines’ service from NHS Choices has featured a quality assessment of press reports that doctors at Moorfields Eye Hospital have been “given the go-ahead” to carry out Europe’s first clinical trial usi…
Local anaesthetic eye drops for prevention of pain in preterm infants undergoing screening for retinopathy of prematurity
Source: Cochrane
Area: Evidence > Drug Specific Reviews
Background
Screening examinations for retinopathy of prematurity (ROP) are performed routinely in the neonatal intensive care unit and are a recognised cause of pain in the newborn.
…
Acupuncture for slowing the progression of myopia in children and adolescents
Source: Cochrane Library
Area: Evidence > Complementary Medicine
Background
Myopia (near-sightedness or short-sightedness) is one of the three commonly detected refractive (focusing) errors. Acupuncture is the stimulation of acupuncture points by …
U.S. Department of Veterans Affairs ceases use of bevacizumab for wet AMD while it investigates reports of increased risk of infection
Source: Reuters Health News
Area: News
According to a Reuters report, the U.S. Department of Veterans Affairs has stopped using bevacizumab to treat wet age-related macular degeneration while it investigates reports of increased risk of infection. Onc…
US FDA approves denosumab for cancer therapy-induced bone loss in women with breast cancer and men with prostate cancer
Source: BioSpace.com
Area: News
The US Food and Drug Administration (FDA) has approved denosumab (Prolia) as a treatment, for the following indications:
. to increase bone mass in women at high risk for fracture receiving adjuvant aromatase in…
Contaminated batches of intravitreal bevacizumab from single pharmacy in US linked to serious eye infections
Source: PharmaTimes
Area: News
The FDA is investigating cases of serious eye infections in patients in Miami who have been treated with repackaged intravitreal bevacizumab for wet age-related macular degeneration. The Agency is alerting healthcare pro…
NICE agrees to review appeal against its decision on ranibizumab for diabetic macular oedema
Source: PharmaLive
Area: News
According to a PharmaLive report, the National Institute for Health and Clinical Excellence (NICE) has agreed to review an appeal against its preliminary decision not to recommend ranibizumab for the treatment of visual i…
Sublingual immunotherapy for treating allergic conjunctivitis
Source: Cochrane Library
Area: Evidence > Drug Specific Reviews
Background
Allergic ocular symptoms, although frequently trivialised, are common and represent an important comorbidity of allergic rhinitis. Sublingual Immunotherapy (SLIT) is an …
NICE issues guidance on dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion (RVO) (TA229)
Source: NICE
Area: Evidence > Guidelines
The National Institute for Health and Clinical Excellence has issued guidance on the use of dexamethasone intravitreal implants for the treatment of macular oedema caused by retinal vein occlusion (RVO).
&nbs…
NICE costing report and template for dexamethasone intravitreal implants for macular oedema caused by retinal vein occlusion
Source: NICE
Area: News
The National Institute for Health and Clinical Excellence (NICE) has published a costing statement to accompany its latest guidance on the use of dexamethasone intravitreal implants for the treatment of macular oedema cau…
NICE FAD does not recommend ranibizumab for treatment of diabetic macular oedema
Source: NICE
Area: News
The National Institute for Health and Clinical Excellence (NICE) has issued its Final Appraisal Determination (FAD) on ranibizumab for the treatment of diabetic macular oedema (DMO). Within the FAD, ranibizumab is not recommend…